New biomarkers of endothelial dysfunction

The influence of perindopril on TSP-1 and PTX3 plasma levels at the beginning and after one year on treatment, in hypertensive patients with endothelial dysfunction

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN92249277

Enrollment

112

Registered

2018-02-25

Start date

2015-01-01

Completion date

Unknown

Last updated

2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential arterial hypertension, endothelial dysfunction Circulatory System Essential (primary) hypertension

Interventions

All recruited patients completed the informed consent form and underwent a thorough screening including the disease and other associated medical conditions, a family medical history, and laboratory/pa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >18 years 2. Established diagnosis of primary arterial hypertension

Exclusion criteria

Exclusion criteria: 1. Atherosclerotic disease 2. Coronary artery disease 3. Heart failure 4. Diabetes 5. Renal and hepatic pathologies 6. Asthma 7. Acute and chronic inflammatory diseases

Design outcomes

Primary

Measure	Time frame
1. Arterial pressure was measured after 30 minutes of rest, in a supine position, at the right brachial artery 2. The presence/absence of endothelial dysfunction was assessed using flow mediated dilation (FMD) and intimal-medial thickness (IMT) 3. Plasma levels of TSP-1, PTX3 (pentraxin-3) and hs-CRP (high-selectivity C reactive protein) measured using the ELISA method (TSP-1, PTX3) and the high sensitive immunoturbidimetric method (hs-CRP) All outcomes measured at baseline and after one year of treatment	—

Measure

Time frame

1. Arterial pressure was measured after 30 minutes of rest, in a supine position, at the right brachial artery 2. The presence/absence of endothelial dysfunction was assessed using flow mediated dilation (FMD) and intimal-medial thickness (IMT) 3. Plasma levels of TSP-1, PTX3 (pentraxin-3) and hs-CRP (high-selectivity C reactive protein) measured using the ELISA method (TSP-1, PTX3) and the high sensitive immunoturbidimetric method (hs-CRP) All outcomes measured at baseline and after one year of treatment

—

Secondary

Measure	Time frame
1. Cardiovascular morbidity and mortality were measured using clinical examination of patients, electrocardiography, blood pressure measurements every time the patients visited the doctor 2. Incidence of strokes, myocardial infarction, and heart failure were measured using electrocardiography, echocardiography by determining the specific parameters in every visit and also by evaluating the presence of clinical symptoms All outcomes measured at baseline and after one year of treatment	—

Measure

Time frame

1. Cardiovascular morbidity and mortality were measured using clinical examination of patients, electrocardiography, blood pressure measurements every time the patients visited the doctor 2. Incidence of strokes, myocardial infarction, and heart failure were measured using electrocardiography, echocardiography by determining the specific parameters in every visit and also by evaluating the presence of clinical symptoms All outcomes measured at baseline and after one year of treatment

—

Countries

Romania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026